Build your career on Magnet.me
Create a profile and receive smart job recommendations based on your liked jobs.
We’re here for one reason and one reason only – to cure cancer. Every moment is dedicated to developing treatments and every action moves us one step closer to our goal. We’ve made incredible scientific breakthroughs and our pioneering personalized CAR T-cell therapies have changed the paradigm. But we're not finished yet.
Join Kite, a Gilead Company, as we make even bigger advances in cancer therapies, and help shape where our business and medical science goes next.
This role is for a MES Validation Specialist (MSAT Process Engineer) at Kite, a Gilead Company.
About the role
As an MSAT Process Engineer focused on MES Validation, you will be the MES SME for risk-based validation and lifecycle management of PAS-X EBRs with knowledge of connected GMP systems (e.g., ERP/EBS). You will lead cross-functional validation strategy and execution for changes and new implementations, ensure end-to-end data integrity and participate in inspections on computerized systems within a commercial cell-therapy manufacturing environment. This is a senior individual-contributor role operating with minimal direction and broad influence across MSAT, Manufacturing and Quality.
Your Responsibilities
MES Validation Expertise & Strategy
EBR Recipe Lifecycle Management
Data Integrity & Interfaces
Operational Support & Continuous Improvement
MES Network & Cross-site alignment
Your Profile
Education
Bachelor’s degree or equivalent experience.
Knowledge and Experience
Personal Skills
Additional requirements
About Kite
Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term durable response and eliminating the burden of chronic care. The company is focused on chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered cell therapies designed to empower the immune system's ability to recognize and kill tumors.
For the past three decades, members of our team have been at the forefront of cancer immunotherapy. Today, we are a leader in engineered T cell therapy, changing the paradigm of cancer treatment with what is potentially the biggest breakthrough since the introduction of combination chemotherapy more than 60 years ago.
View what's on offer:
Change language to: Dutch
This page is optimised for people from the Netherlands. View the version optimised for people from the UK.